Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare... Show more
On November 11, 2025, the Stochastic Oscillator for MKGAF moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 63 instances where the indicator left the oversold zone. In of the 63 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The Momentum Indicator moved above the 0 level on November 13, 2025. You may want to consider a long position or call options on MKGAF as a result. In of 118 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MKGAF just turned positive on November 13, 2025. Looking at past instances where MKGAF's MACD turned positive, the stock continued to rise in of 61 cases over the following month. The odds of a continued upward trend are .
MKGAF moved above its 50-day moving average on November 13, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MKGAF advanced for three days, in of 220 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day moving average for MKGAF crossed bearishly below the 50-day moving average on November 06, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MKGAF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MKGAF broke above its upper Bollinger Band on November 13, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MKGAF entered a downward trend on November 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.881) is normal, around the industry mean (17.783). P/E Ratio (18.558) is within average values for comparable stocks, (71.241). Projected Growth (PEG Ratio) (1.416) is also within normal values, averaging (1.857). Dividend Yield (0.018) settles around the average of (0.031) among similar stocks. P/S Ratio (2.506) is also within normal values, averaging (37.821).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MKGAF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MKGAF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Industry PharmaceuticalsGeneric
A.I.dvisor indicates that over the last year, MKGAF has been loosely correlated with MKKGY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MKGAF jumps, then MKKGY could also see price increases.
| Ticker / NAME | Correlation To MKGAF | 1D Price Change % | ||
|---|---|---|---|---|
| MKGAF | 100% | +8.55% | ||
| MKKGY - MKGAF | 49% Loosely correlated | +4.80% | ||
| AQST - MKGAF | 19% Poorly correlated | -5.02% | ||
| INDV - MKGAF | 17% Poorly correlated | -0.90% | ||
| EVO - MKGAF | 17% Poorly correlated | +0.96% | ||
| EBS - MKGAF | 16% Poorly correlated | -4.53% | ||
More | ||||
| Ticker / NAME | Correlation To MKGAF | 1D Price Change % |
|---|---|---|
| MKGAF | 100% | +8.55% |
| Pharmaceuticals: Generic industry (214 stocks) | 36% Loosely correlated | -0.08% |